757 related articles for article (PubMed ID: 25252957)
1. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.
Eming R; Hennerici T; Bäcklund J; Feliciani C; Visconti KC; Willenborg S; Wohde J; Holmdahl R; Sønderstrup G; Hertl M
J Immunol; 2014 Nov; 193(9):4391-9. PubMed ID: 25252957
[TBL] [Abstract][Full Text] [Related]
2. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris.
Schmidt T; Willenborg S; Hünig T; Deeg CA; Sonderstrup G; Hertl M; Eming R
Exp Dermatol; 2016 Apr; 25(4):293-8. PubMed ID: 26661498
[TBL] [Abstract][Full Text] [Related]
3. Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramers.
Veldman C; Eming R; Wolff-Franke S; Sonderstrup G; Kwok WW; Hertl M
Clin Immunol; 2007 Mar; 122(3):330-7. PubMed ID: 17113829
[TBL] [Abstract][Full Text] [Related]
4. Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris.
Didona D; Scarsella L; Hudemann C; Volkmann K; Zimmer CL; Beckert B; Tikkanen R; Korff V; Kühn K; Wienzek-Lischka S; Bein G; Di Zenzo G; Böhme J; Cunha T; Solimani F; Pieper J; Juratli HA; Göbel M; Schmidt T; Borradori L; Yazdi AS; Sitaru C; Garn H; Eming R; Fleischer S; Hertl M
J Invest Dermatol; 2024 Feb; 144(2):263-272.e8. PubMed ID: 37717934
[TBL] [Abstract][Full Text] [Related]
5. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.
Pollmann R; Schmidt T; Eming R; Hertl M
Clin Rev Allergy Immunol; 2018 Feb; 54(1):1-25. PubMed ID: 29313220
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris.
Hertl M; Riechers R
J Dermatol; 1999 Nov; 26(11):748-52. PubMed ID: 10635617
[TBL] [Abstract][Full Text] [Related]
7. Autoreactive B-cell elimination by pathogenic IgG specific for the same antigen: implications for peripheral tolerance.
Ota T; Aoki-Ota M; Tsunoda K; Nishikawa T; Koyasu S; Amagai M
Int Immunol; 2008 Oct; 20(10):1351-60. PubMed ID: 18765425
[TBL] [Abstract][Full Text] [Related]
8. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice.
Aoki-Ota M; Tsunoda K; Ota T; Iwasaki T; Koyasu S; Amagai M; Nishikawa T
Br J Dermatol; 2004 Aug; 151(2):346-54. PubMed ID: 15327541
[TBL] [Abstract][Full Text] [Related]
9. Pemphigus vulgaris and its active disease mouse model.
Amagai M
Curr Dir Autoimmun; 2008; 10():167-81. PubMed ID: 18460885
[TBL] [Abstract][Full Text] [Related]
10. Prediction of desmoglein-3 peptides reveals multiple shared T-cell epitopes in HLA DR4- and DR6-associated pemphigus vulgaris.
Tong JC; Tan TW; Sinha AA; Ranganathan S
BMC Bioinformatics; 2006 Dec; 7 Suppl 5(Suppl 5):S7. PubMed ID: 17254312
[TBL] [Abstract][Full Text] [Related]
11. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris.
Müller R; Svoboda V; Wenzel E; Müller HH; Hertl M
Exp Dermatol; 2008 Jan; 17(1):35-43. PubMed ID: 18095943
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris.
Tsunoda K; Ota T; Suzuki H; Ohyama M; Nagai T; Nishikawa T; Amagai M; Koyasu S
Eur J Immunol; 2002 Mar; 32(3):627-33. PubMed ID: 11857336
[TBL] [Abstract][Full Text] [Related]
13. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface.
Di Zenzo G; Di Lullo G; Corti D; Calabresi V; Sinistro A; Vanzetta F; Didona B; Cianchini G; Hertl M; Eming R; Amagai M; Ohyama B; Hashimoto T; Sloostra J; Sallusto F; Zambruno G; Lanzavecchia A
J Clin Invest; 2012 Oct; 122(10):3781-90. PubMed ID: 22996451
[TBL] [Abstract][Full Text] [Related]
14. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles.
Veldman C; Stauber A; Wassmuth R; Uter W; Schuler G; Hertl M
J Immunol; 2003 Jan; 170(1):635-42. PubMed ID: 12496453
[TBL] [Abstract][Full Text] [Related]
15. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
[TBL] [Abstract][Full Text] [Related]
16. Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice.
Hofrichter M; Dworschak J; Emtenani S; Langenhan J; Weiß F; Komorowski L; Zillikens D; Stöcker W; Probst C; Schmidt E; Goletz S
Front Immunol; 2018; 9():1935. PubMed ID: 30233569
[TBL] [Abstract][Full Text] [Related]
17. A single helper T cell clone is sufficient to commit polyclonal naive B cells to produce pathogenic IgG in experimental pemphigus vulgaris.
Takahashi H; Kuwana M; Amagai M
J Immunol; 2009 Feb; 182(3):1740-5. PubMed ID: 19155523
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris.
Lin MS; Swartz SJ; Lopez A; Ding X; Fernandez-Vina MA; Stastny P; Fairley JA; Diaz LA
J Clin Invest; 1997 Jan; 99(1):31-40. PubMed ID: 9011573
[TBL] [Abstract][Full Text] [Related]
19. Keratin Retraction and Desmoglein3 Internalization Independently Contribute to Autoantibody-Induced Cell Dissociation in Pemphigus Vulgaris.
Schlögl E; Radeva MY; Vielmuth F; Schinner C; Waschke J; Spindler V
Front Immunol; 2018; 9():858. PubMed ID: 29922278
[No Abstract] [Full Text] [Related]
20. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris.
Amber KT; Staropoli P; Shiman MI; Elgart GW; Hertl M
Exp Dermatol; 2013 Nov; 22(11):699-704. PubMed ID: 24433179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
